Characteristics of hepatic IGF-II expression and monitored levels of circulating IGF-II mRNA in metastasis of hepatocellular carcinoma

American Journal of Clinical Pathology

Volumn 134, Issue 5, 2010, Pages 799-806

  Qian, Jing ^a   Yao, Dengfu ^a   Dong, Zhizhen ^a   Wu, Wei ^a   Qiu, Liwei ^a   Yao, Ninghua ^a   Li, Shanshan ^a   Bian, Yinzhu ^a   Wang, Zhiwei ^a   Shi, Gongsheng ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Gene amplification; Hepatocellular carcinoma; IGF II mRNA; Insulin like growth factor II (IGF II); Metastasis; Peripheral blood mononuclear cells

Indexed keywords

ALPHA FETOPROTEIN; COMPLEMENTARY DNA; MESSENGER RNA; SOMATOMEDIN B;

ADULT; AGE; AGED; ARTICLE; FEMALE; GENDER; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RNA EXTRACTION; TUMOR VOLUME; CHI SQUARE DISTRIBUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; LIVER TUMOR; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LEUKOCYTES, MONONUCLEAR; LIVER; LIVER NEOPLASMS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 78049493169     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPTFDSE2V3LCZP     Document Type: Article

References (39)

1. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047-2063.
2. Yao DF, Jiang DR, Huang ZW, et al. Abnormal expression of hepatoma specific γ-glutamyl transferase and alteration of γ-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer. 2000;88:761-769.
3. Orito E, Mizokami M. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Intervirology. 2003;46:408-412. (Pubitemid 38037042)
4. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312-1327.
5. Jia HL, Ye QH, Qin LX, et al. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res. 2007;13:1133-1139. (Pubitemid 46424052)
6. Yao DF, Dong ZZ, Yao M. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2007;6:241-247. (Pubitemid 46925243)
7. Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin Liver Dis. 2006;26:385-390.
8. Nussbaum T, Samarin J, Ehemann V, et al. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology. 2008;48:146-156.
9. Breuhahn K, Schirmacher P. Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World J Gastroenterol. 2008;14:1690-1698.
10. Couvert P, Carrié A, Pariès J, et al. Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma. World J Gastroenterol. 2008;14:5419-5427.
11. Jeng YM, Chang CC, Hu FC, et al. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology. 2008;48:1118-1127.
12. Tang SH, Yang DH, Huang W, et al. Differential promoter usage for insulin-like growth factor-II gene in Chinese hepatocellular carcinoma with hepatitis B virus infection. Cancer Detect Prev. 2006;30:192-203.
13. Wu J, Qin Y, Li B, et al. Hypomethylated and hypermethylated profiles of H19DMR are associated with the aberrant imprinting of IGF2 and H19 in human hepatocellular carcinoma. Genomics. 2008;91:443-450.
14. Chen YW, Boyartchuk V, Lewis BC. Differential roles of insulin-like growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells. Neoplasia. 2009;11:835-845.
15. Qiu LW, Yao DF, Zong L, et al. Abnormal expression of insulin-like growth factor-II and its dynamic quantitative analysis at different stages of hepatocellular carcinoma development. Hepatobiliary Pancreat Dis Int. 2008;7:406-411.
16. Dong ZZ, Yao DF, Yao DB, et al. Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J Gastroenterol. 2005;11:4655-4660.
17. Cheng W, Tseng CJ, Lin TT, et al. Glypican-3-mediated oncogenesis involves the insulin-like growth factor-signaling pathway. Carcinogenesis. 2008;29:1319-1326.
18. Wu W, Yao DF, Yuan YM, et al. Combined serum hepatoma-specific AFP and circulating AFP-mRNA analysis for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2006;5:538-544.
19. The Liver Cancer Committee of Chinese Anticancer Association. Diagnostic criteria of primary hepatocellular carcinoma [in Chinese]. Zhonghua Gan Zang Bing Za Zhi. 2000;8:135.
20. The Group of Viral Hepatitis Research. The prevention and cure scheme of viral hepatitis [in Chinese]. Zhonghua Gan Zang Bing Za Zhi. 2000;8:324-329.
21. Rall LB, Scott J, Bell GI. Human insulin-like growth factor I and II messenger RNA: isolation of complementary DNA and analysis of expression. Methods Enzymol. 1987;146:239-248.
22. Benham FJ, Povey S. Members of the human glyceraldehyde-3-phosphate dehydrogenase-related gene family map to dispersed chromosomal locations. Genomics. 1989;5:209-214.
23. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science. 2005;307:1976-1978.
24. Tang SH, Yang DH, Huang W, et al. Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population. Clin Cancer Res. 2006;12:4171-4177.
25. Fukuda I, Hizuka N, Ishikawa Y. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res. 2006;16:211-216.
26. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther. 2007;6:2158-2167.
27. Slosar M, Vohra P, Prasad M, et al. Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol. 2009;20:149-157.
28. Zhou HK, Yang DH, Tang SH, et al. Construction of a plasmid vector of fused protein genes driven by human insulin-like growth factor II P3 promoter [in Chinese]. Zhonghua Yi Xue Za Zhi. 2006;86:106-110.
29. Longato L, de la Monte S, Kuzushita N, et al. Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology. 2009;49:1935-1943.
30. Yao DF, Jiang H, Yao M, et al. Quantitative analysis of hepatic hypoxia-inducible factor-1 alpha and its abnormal gene expression during the formation of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2009;8:407-413.
31. Bae MH, Lee MJ, Bae SK, et al. Insulin-like growth factor II (IGF-II) secreted from HepG2 human hepatocellular carcinoma cells shows angiogenic activity. Cancer Lett. 1998;128:41-46.
32. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-660.
33. Chan DW, Ng IO. Knock down of hepatitis B virus X protein reduces the tumorigenicity of hepatocellular carcinoma cells. J Pathol. 2006;208:372-380.
34. Spangenberg HC, Thimme R, Blum HE. Evolving therapies in the treatment of hepatocellular carcinoma. Biologics. 2008;2:453-462.
35. Funaki NO, Tanaka J, Seto SI, et al. Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver. Hepatology. 1997;25:564-568.
36. Scharf JG, Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res. 2003;35:685-693.
37. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339-346.
38. Cantarini MC, de la Monte SM, Pang M, et al. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology. 2006;44:446-457.
39. Morisawa T, Marusawa H, Ueda Y, et al. Organ-specific profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression. Int J Cancer. 2008;123:2735-2740.